Van Deijk W A, Blijham G H, Mellink W A, Meulenberg P M
Cancer Treat Rep. 1985 Jan;69(1):85-90.
Postmenopausal patients with metastatic breast cancer were treated with aminoglutethimide (AG) and high-dose medroxyprogesterone acetate (MPA). Studying the interaction between the two drugs as far as plasma MPA and cortisol levels are concerned we observed a 50% decrease of plasma MPA levels after the addition of AG (P less than 0.005). With large interindividual differences in plasma MPA levels, a significant correlation with serum cortisol levels was found (P less than 0.001). It can be concluded that AG leads to a lowering of plasma MPA levels to such an extent that its adrenal suppressive effect may be diminished or even abrogated. In future trials of MPA with or without AG correlations between plasma MPA levels, serum cortisol levels and treatment response should be taken into account.
绝经后转移性乳腺癌患者接受了氨鲁米特（AG）和大剂量醋酸甲羟孕酮（MPA）治疗。就血浆MPA和皮质醇水平而言，研究这两种药物之间的相互作用时，我们观察到添加AG后血浆MPA水平下降了50%（P<0.005）。血浆MPA水平存在较大个体差异，与血清皮质醇水平存在显著相关性（P<0.001）。可以得出结论，AG导致血浆MPA水平降低到其肾上腺抑制作用可能减弱甚至消除的程度。在未来使用或不使用AG的MPA试验中，应考虑血浆MPA水平、血清皮质醇水平与治疗反应之间的相关性。
